The incidence of gram-negative multi-drug–resistant (MDR) infections is increasing worldwide. This study sought to determine the incidence, clinical profiles, risk factors, and mortality of these infections in general surgery patients.
Patients and Methods:
All general surgery patients with a clinical infection by gram-negative MDR bacteria were studied prospectively for a period of five years (2007–2011). Clinical, surgical, and microbiologic parameters were recorded, with a focus on the identification of risk factors for MDR infection and mortality.
Results:
Incidence of MDR infections increased (5.6% to 15.2%) during the study period; 106 patients were included, 69.8% presented nosocomial infections. Mean age was 65 ± 15 years, 61% male. Extended-spectrum β-lactamases (ESBL) Escherichia coli was the most frequent MDR bacteria. Surgical site infections and abscesses were the most common culture locations. The patients presented multiple pre-admission risk factors and invasive measures during hospitalization. Mortality was 15%, and related to older age (odds ratio [OR] 1.07), malnutrition (OR 13.5), chronic digestive conditions (OR 4.7), chronic obstructive pulmonary disease (OR 3.9), and surgical re-intervention (OR 9.2).
Conclusion:
Multi-drug resistant infections in the surgical population are increasing. The most common clinical profile is a 65-year-old male, with previous comorbidities, who has undergone a surgical intervention, intensive care unit (ICU) admission, and invasive procedures and who has acquired the MDR infection in the nosocomial setting.
Get full access to this article
View all access options for this article.
References
1.
ChenY-H, HsuehP-R. Changing bacteriology of abdominal and surgical sepsis. Curr Opin Infect Dis, 2012; 25:590–595.
2.
CoqueTM, BaqueroF, CantonR. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill, 2008; 13:pii:19044.
3.
GuptaV. An update on newer beta-lactamases. Indian J Med Res, 2007; 126:417–427.
4.
PatersonDL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med, 2006; 119:20–28.
5.
Rodríguez-MartínezJM, PascualA, GarcíaI, et al.Detection of the plasmid-mediated quinolone resistance determinant qnr among clinical isolates of Klebsiella pneumoniae producing AmpC-type beta-lactamase. J Antimicrob Chemother, 2003; 52:703–706.
6.
LivermoreDM, WarnerM, MushtaqS, et al.What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents, 2011; 37:415–419.
7.
HaYE, KangC-I, ChaMK, et al.Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents, 2013; 42:403–409.
8.
BukeC, Armand-LefevreL, LolomI, et al.Epidemiology of multidrug-resistant bacteria in patients with long hospital stays. Infect Control Hosp Epidemiol, 2007; 28:1255–1260.
9.
RazaziK, DerdeLPG, VerachtenM, et al.Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Med, 2012; 38:1769–1778.
10.
TamVH, RogersCA, ChangK-T, et al.Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother, 2010; 54:3717–3722.
11.
NathwaniD, RamanG, SulhamK, et al.Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control, 2014; 3:32.
12.
Rodríguez-BañoJ, NavarroMD, RomeroL, et al.Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol, 2004; 42:1089–1094.
13.
ValverdeA, GrillF, CoqueTM, et al.High rate of intestinal colonization with extended-spectrum-β-lactamase–producing organisms in household contacts of infected community patients. J Clin Microbiol, 2008; 46:2796–2799.
14.
GalasM, DecousserJ-W, BretonN, et al.Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in France. Antimicrob Agents Chemother, 2008; 52:786–789.
15.
DíazMA, Hernandez-BelloJR, Rodriguez-BañoJ, et al.Diversity of Escherichia coli strains producing extended-spectrum β-lactamases in Spain: Second nationwide study. J Clin Microbiol, 2010; 48:2840–2845.
16.
CantónR, LozaE, AznarJ, et al.Antimicrobial susceptibility of gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002–2010). Rev Esp Quimioter, 2011; 24:223–232.
17.
SamonisG, KarageorgopoulosDE, MarakiS, et al.Stenotrophomonas maltophilia infections in a general hospital: Patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS One, 2012; 7:e37375.
18.
SalvadorVBDG, LozadaMCH, ConsunjiRJ. Microbiology and antibiotic susceptibility of organisms in bile cultures from patients with and without cholangitis at an Asian academic medical center. Surg Infect, 2011; 12:105–111.
19.
SchwaberMJ, Navon-VeneziaS, KayeKS, et al.Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother, 2006; 50:1257–1262.
20.
GaraziM, SingerC, TaiJ, et al.Bloodstream infections caused by Stenotrophomonas maltophilia: A seven-year review. J Hosp Infect, 2012; 81:114–118.
21.
Rubio-PerezI, Martin-PerezE, DomingoD, et al.Extended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: Epidemiology, risk factors and antimicrobial susceptibility patterns. Emerg Heal Threat J, 2012; 1:11589.
22.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: 18th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute.
23.
European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2011. 2011 Annual Report or the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2012. http://ecdc.europa.eu/en/publications/ (Last accessed April6, 2017).
CantónR, AznarJ, CercenadoE, et al.Original antimicrobial susceptibility of fram-negative organisms from intra abdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002–2010). Rev Esp Quimioter, 2011; 24:223–232.
26.
HawserS, HobanD, BouchillonS, et al.Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis, 2011; 30:173–179.
27.
FernandesR, PrudêncioC. Post-surgical wound infections involving Enterobacteriaceae with reduced susceptibility to β-lactams in two Portuguese hospitals. Int Wound J, 2010; 7:508–514.
28.
SeniJ, NajjukaCF, KateeteDP, et al.Antimicrobial resistance in hospitalized surgical patients: a silently emerging public health concern in Uganda. BMC Res Notes, 2013; 6:298.
29.
MontesCV, Vilar-CompteD, VelazquezC, et al.Risk factors for extended spectrum β-lactamase-producing Escherichia coli versus susceptible E. coli in surgical site infections among cancer patients in Mexico. Surg Infect, 2014; 15:627–634.
30.
GuptaN, SohanlalT, SomanR, et al.The relevance of ESBL producing isolates in patients surgically treated for acute appendicitis. J Assoc Physicians India, 2011; 59:293–295.
31.
MontraversP, GauzitR, MullerC, et al.Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis, 1996; 23:486–494.
32.
AugustinP, KermarrecN, Muller-SerieysC, et al.Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care, 2010; 14:R20.
33.
SolomkinJS, MazuskiJE, BradleyJS, et al.Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis, 2010; 50:133–164.
34.
Rodriguez-BañoJ, López- CereroL, NavarroMD, et al.Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli: Prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother, 2008; 62:1142–1149.
35.
MesaRJ, BlancV, BlanchAR, et al.Extended-spectrum beta-lactamase-producing Enterobacteriaceae in different environments (humans, food, animal farms and sewage). J Antimicrob Chemother, 2006; 58:211–215.
36.
BroadersE, GahanCGM, MarchesiJR. Mobile genetic elements of the human gastrointestinal tract: Potential for spread of antibiotic resistance genes. Gut Microbes, 2013; 4:271–280.
37.
ChabokA, TärnbergM, SmedhK, et al.Prevalence of fecal carriage of antibiotic-resistant bacteria in patients with acute surgical abdominal infections. Scand J Gastroenterol, 2010; 45:1203–1210.
38.
PeraltaG, LameloM, Alvarez-GarcíaP, et al.Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis, 2012; 12:245.
39.
GudiolC, CalatayudL, Garcia-VidalC, et al.Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: Clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother, 2010; 65:333–341.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
